Compare ZUMZ & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZUMZ | DMAC |
|---|---|---|
| Founded | 1978 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.1M | 457.2M |
| IPO Year | 2005 | N/A |
| Metric | ZUMZ | DMAC |
|---|---|---|
| Price | $28.61 | $8.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $15.50 |
| AVG Volume (30 Days) | 313.5K | ★ 551.3K |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $916,909,000.00 | N/A |
| Revenue This Year | $5.50 | N/A |
| Revenue Next Year | $1.36 | N/A |
| P/E Ratio | $59.11 | ★ N/A |
| Revenue Growth | ★ 2.81 | N/A |
| 52 Week Low | $11.31 | $3.19 |
| 52 Week High | $31.70 | $10.42 |
| Indicator | ZUMZ | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 49.85 |
| Support Level | $28.55 | $8.40 |
| Resistance Level | $29.68 | $10.14 |
| Average True Range (ATR) | 1.19 | 0.72 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 48.86 | 15.04 |
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.